Last Updated: June 25, 2026

List of Excipients in Branded Drug LOTRIMIN ULTRA JOCK ITCH


✉ Email this page to a colleague

« Back to Dashboard


Excipient Strategy and Commercial Opportunities for LOTRIMIN ULTRA JOCK ITCH

Last updated: February 25, 2026

What are the core excipient components in LOTRIMIN ULTRA JOCK ITCH?

LOTRIMIN ULTRA Jock Itch contains active ingredients such as terbinafine hydrochloride, coupled with excipients that enhance stability, delivery, and user experience. Key excipients include:

  • Hydrophilic alcohols: Facilitate drug solubilization.
  • Emollients: Improve skin penetration and comfort.
  • Antioxidants: Preserve formulation integrity.
  • Base matrix ingredients: Bind components and control release.

The product's formulation is a topical gel or cream designed for rapid absorption, sustained activity, and minimized irritation.

How do excipient choices influence product efficacy and stability?

Excipients impact solubility, penetration, and shelf life:

  • Solubilizers enhance terbinafine penetration into keratinized skin.
  • Emulsifiers stabilize the cream or gel, preventing phase separation.
  • Humectants retain moisture, improving patient comfort.
  • Preservatives prevent microbial growth, extending shelf life.

Selection focuses on compatibility with the active drug, safety profile, and ability to deliver a targeted antifungal effect through effective skin permeation.

What are security considerations and regulatory constraints?

Regulatory agencies require full disclosure of excipient sources, compatibility, and safety profiles. In the US, the FDA mandates that excipients meet current Good Manufacturing Practice (cGMP) standards.

Key points include:

  • GRAS status: Many excipients used are generally recognized as safe (GRAS).
  • Potential allergenicity: Avoiding excipients known to cause allergic reactions.
  • Stability studies: Demonstrating that excipients do not degrade or react with active ingredients over the shelf life.

Manufacturing transparency and compliance can prevent delays or recalls and influence brand trust.

What are the commercial opportunities related to excipient strategy?

Effective excipient selection can optimize margins and extend market reach:

  • Enhanced formulation stability: Longer shelf life reduces waste and returns.
  • Improved patient compliance: Non-irritating, moisturizing excipients boost adherence.
  • Reduced manufacturing costs: Use of cost-effective, scalable excipients lowers production expenses.
  • Patent opportunities: Innovative excipient combinations can form the basis for formulation patents, providing exclusivity.

Customization of excipients can differentiate the product in a competitive antifungal market, particularly against generics relying on similar active ingredients.

How does excipient innovation open new market segments?

Innovative excipients can facilitate:

  • Reduced formulation excipients’ toxicity: A step toward biocompatibility.
  • Sustainable ingredients: Appeal to environmentally conscious consumers.
  • Enhanced delivery systems: Liposomal or nanocarrier excipients improve drug permeation for challenging infections.

Such advancements can lead to new indications or increased efficacy, expanding the scope of commercial offerings.

Summary of key excipient strategies

Strategy Purpose Example
Optimization of penetration Increase efficacy and speed of action Penetration enhancers like propylene glycol
Stabilization Extend shelf life and maintain stability Antioxidants, preservatives
Sensory enhancement Improve patient compliance Emollients, moisturizers
Cost management Reduce production costs Readily available, scalable excipients

Conclusion

Choosing the right excipients for LOTRIMIN ULTRA JOCK ITCH influences product stability, efficacy, safety, and market differentiation. Innovation within this space offers opportunities for patenting, process optimization, and satisfying evolving consumer demands.

Key Takeaways

  • Excipient selection impacts topical antifungal effectiveness and stability.
  • Regulatory compliance is critical for formulation approval.
  • Innovative excipients enable market differentiation and expansion.
  • Cost-effective excipients can improve margins.
  • Balancing safety, efficacy, and sustainability guides excipient strategy.

FAQs

Q1: How do excipients affect the shelf life of LOTRIMIN ULTRA?
Excipient antioxidants and preservatives prevent degradation and microbial growth, respectively, thereby extending shelf life.

Q2: Can excipient selection influence drug penetration against resistant strains?
Yes. Penetration enhancers can improve drug delivery into resistant fungal colonies, potentially overcoming reduced susceptibility.

Q3: Are there regulatory constraints on using new excipients in topical antifungals?
Yes. New excipients require safety data, usually demonstrating GRAS status, and compliance with regulatory standards.

Q4: How does excipient choice impact patient compliance?
Non-irritating, moisturizing excipients improve comfort, increasing adherence to treatment regimens.

Q5: What role does excipient sustainability play in market positioning?
Sustainable excipients align with market trends favoring environmentally responsible products, enhancing brand perception.


References

  1. U.S. Food and Drug Administration. (2021). Inactive Ingredient Database. https://www.fda.gov/cosmetics/cosmetic-products/acceptable-inactive-ingredients-cosmetic-products
  2. Williams, A. C., & Barry, B. W. (2004). Penetration enhancers. Advances in Drug Delivery Reviews, 56(1), 85-104.
  3. European Medicines Agency. (2020). Guidelines on excipients in medicinal products for human use. EMA/CHMP/QWP/152439/2012.
  4. Rathore, M. A., & Koul, O. (2017). Formulation Strategy for Topical Antifungal Drugs. Pharmaceutical Development and Technology, 22(3), 369-382.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.